These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17579511)

  • 21. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control and prevention of avian influenza in an evolving scenario.
    Capua I; Marangon S
    Vaccine; 2007 Jul; 25(30):5645-52. PubMed ID: 17169466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA-based influenza vaccines: evaluating their potential to provide universal protection.
    Choo AY; Broderick KE; Kim JJ; Sardesai NY
    IDrugs; 2010 Oct; 13(10):707-12. PubMed ID: 20878593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of vaccines and vaccination on global control of avian influenza.
    Swayne DE
    Avian Dis; 2012 Dec; 56(4 Suppl):818-28. PubMed ID: 23402099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for pandemic influenza.
    Luke CJ; Subbarao K
    Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New vaccine approaches for seasonal and pandemic influenza.
    Palache B
    Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza: current threat from avian influenza.
    Stephenson I; Democratis J
    Br Med Bull; 2005; 75-76():63-80. PubMed ID: 16651383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Avian influenza and perspectives on vaccination against pandemic influenza].
    Holst PJ; Christensen JP; Thomsen AR
    Ugeskr Laeger; 2008 Nov; 170(48):3953-6. PubMed ID: 19087735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.
    Leahy TR; Smith OP; Bacon CL; Storey L; Lynam P; Gavin PJ; Butler KM; O'Marcaigh AS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1656-61. PubMed ID: 23682005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for a potential influenza pandemic.
    Auewarakul P; Thongcharoen P
    Future Microbiol; 2007 Jun; 2(3):345-9. PubMed ID: 17661708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which factors are important in adults' uptake of a (pre)pandemic influenza vaccine?
    Zijtregtop EA; Wilschut J; Koelma N; Van Delden JJ; Stolk RP; Van Steenbergen J; Broer J; Wolters B; Postma MJ; Hak E
    Vaccine; 2009 Dec; 28(1):207-27. PubMed ID: 19800997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States.
    Wu JT; Riley S; Leung GM
    Proc Biol Sci; 2007 Nov; 274(1627):2811-7. PubMed ID: 17785273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finding optimal vaccination strategies for pandemic influenza using genetic algorithms.
    Patel R; Longini IM; Halloran ME
    J Theor Biol; 2005 May; 234(2):201-12. PubMed ID: 15757679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
    Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
    Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The United States vaccine supply: challenges in preparing for an avian influenza pandemic.
    Straus WL
    Yale J Biol Med; 2005 Oct; 78(5):255-64. PubMed ID: 17132332
    [No Abstract]   [Full Text] [Related]  

  • 38. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mass vaccination for annual and pandemic influenza.
    Schwartz B; Wortley P
    Curr Top Microbiol Immunol; 2006; 304():131-52. PubMed ID: 16989268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The risk of seasonal and pandemic influenza: prospects for control.
    Monto AS
    Clin Infect Dis; 2009 Jan; 48 Suppl 1():S20-5. PubMed ID: 19067611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.